← Eichor
Condition: Overlap Syndrome Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Overlap Syndrome

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Oral Itraconazole Versus Combination of Systemic Glucorticoids and Oral Itraconazole in CPA-ABPA Overlap Syndrome
NA · 2 location(s) · Post Graduate Institute of Medical Education and Research, C · NCT05444946
Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplas
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT07228624
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
Phase 1/Phase 2 · 4 location(s) · Michael Savona · NCT04061421
Intermittent Hypoxia-initiated Plasticity in Humans: A Multi-pronged Therapeutic Approach to Treat Sleep Apnea and Overl
Phase 1/Phase 2 · 1 location(s) · VA Office of Research and Development · NCT05558501
EPPIC: Easing Pelvic Pain Interventions Clinical Research Program
NA · 3 location(s) · State University of New York at Buffalo · NCT05127616
Impact of Continuous Positive Airway Pressure on the Occurrence of Acute Exacerbations of COPD in Patients With COPD-OSA
NA · 15 location(s) · University Hospital, Angers · NCT05958563
Musculoskeletal and Pelvic Floor Health in Female Chronic Overlapping Pelvic Pain Conditions
Phase N/A · 1 location(s) · Loyola University · NCT05750212
LYell SYndrome MEsenchymal Stromal Cells Treatment
Phase 1/Phase 2 · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT04711200
The Effect of Interval Exercise on Functional Outcomes in Veterans With COPD and OSA
NA · 1 location(s) · VA Office of Research and Development · NCT05254431
Effect of Video Game-Based Breathing Exercises on Respiratory Dysfunction in ACOS
NA · 1 location(s) · Istinye University · NCT07185178
Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Ove
EARLY_Phase 1 · 1 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT07071155
Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
Phase N/A · 19 location(s) · Blueprint Medicines Corporation · NCT07143669
Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MP
Phase 1 · 1 location(s) · Mayo Clinic · NCT05549661
The Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome)
Phase 2 · 1 location(s) · University of California, San Diego · NCT05237505
Diaphragmatic Function and Respiratory Drive in OSA and COPD
Phase N/A · 1 location(s) · Nanjing Medical University · NCT07003399
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, M
Phase 1/Phase 2 · 1 location(s) · Uma Borate · NCT06523556
Impact of Positive Airway Pressure Therapy on Clinical Outcomes in Older Veterans With Chronic Obstructive Pulmonary Dis
NA · 1 location(s) · VA Office of Research and Development · NCT04179981
Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
NA · 1 location(s) · VA Office of Research and Development · NCT02703207
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
Phase 1 · 2 location(s) · Dana-Farber Cancer Institute · NCT06138587
Canadian Network for Autoimmune Liver Disease
Phase N/A · 15 location(s) · University Health Network, Toronto · NCT03569826
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.